


I hereby certify that this paper is being deposited with the United States Postal Service as first class mail, postage prepaid, in an envelope addressed to: Assistant Commissioner for Patents, Washington, DC 20231 on this date:

Dated: August 21, 2002

Signature: Andrew M. Lawrence

(Andrew M. Lawrence)



Docket No.: 27866/370A  
(PATENT)

RECEIVED  
AUG 27 2002  
TECH CENTER 1600  
# 7  
DNT  
9-20-02

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:  
Donald E. Staunton

Application No.: 09/976,935

Group Art Unit: 1646

Filed: October 12, 2001

Examiner: Not Yet Assigned

For: Materials And Methods To Modulate Ligand  
Binding/Enzymatic Activity Of Alpha/Beta  
Proteins Containing An Allosteric Regulatory  
Site

### INFORMATION DISCLOSURE STATEMENT (IDS)

Assistant Commissioner for Patents  
Washington, DC 20231

Dear Sir:

The patents and/or publications listed on the enclosed PTO Form-1449 are submitted pursuant to 37 CFR §§ 1.56, 1.97, and 1.98. Copies of the patents or publications are enclosed as necessary.

This IDS is not intended to be an admission that a search has been made or that any of the documents constitute statutory prior art.

This statement and PTO-1449 form are submitted before receipt of a first Office Action in the above-identified patent application. Accordingly, the Applicant believes there are no fees due at this time. However, the Commissioner is hereby authorized to charge any deficiency in the amount enclosed or any additional fees which may be required to Deposit Account No. 13-2855. A duplicate of this paper is enclosed.

Dated: August 21, 2002

Respectfully submitted,

By: Andrew M. Lawrence

Andrew M. Lawrence, Reg. No. 46,130  
MARSHALL, GERSTEIN & BORUN  
6300 Sears Tower  
233 S. Wacker Drive  
Chicago, Illinois 60606-6357  
(312) 474-6300  
Attorneys for Applicant

I hereby certify that this paper is being deposited with the United States Postal Service as first class mail, postage prepaid, in an envelope addressed to: Assistant Commissioner for Patents, Washington, DC 20231 on this date:

Dated: August 21, 2002

Signature:

*Andrew M. Lawrence*  
(Andrew M. Lawrence)



Docket No.: 2001/0012901

TECH CENTER 1800/2901

AUG 27 2002

RECEIVED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:  
Donald E. Staunton

Application No.: 09/976,935

Group Art Unit: 1646

Filed: October 12, 2001

Examiner: Not Yet Assigned

For: Materials And Methods To Modulate Ligand  
Binding/Enzymatic Activity Of Alpha/Beta  
Proteins Containing An Allosteric Regulatory  
Site

**INFORMATION DISCLOSURE STATEMENT (IDS)**

Assistant Commissioner for Patents  
Washington, DC 20231

Dear Sir:

The patents and/or publications listed on the enclosed PTO Form-1449 are submitted pursuant to 37 CFR §§ 1.56, 1.97, and 1.98. Copies of the patents or publications are enclosed as necessary.

This IDS is not intended to be an admission that a search has been made or that any of the documents constitute statutory prior art.

This statement and PTO-1449 form are submitted before receipt of a first Office Action in the above-identified patent application. Accordingly, the Applicant believes there are no fees due at this time. However, the Commissioner is hereby authorized to charge any deficiency in the amount enclosed or any additional fees which may be required to Deposit Account No. 13-2855. A duplicate of this paper is enclosed.

Dated: August 21, 2002

Respectfully submitted,

By:

*Andrew M. Lawrence*

Andrew M. Lawrence, Reg. No. 46,130  
MARSHALL, GERSTEIN & BORUN  
6300 Sears Tower  
233 S. Wacker Drive  
Chicago, Illinois 60606-6357  
(312) 474-6300  
Attorneys for Applicant



RECEIVED

TECH CENTER 1600/2900

AUG 27 2002

Form PTO-1449 (Modified)

U.S. Department of Commerce  
Patent and Trademark OfficeAtty. Docket No.  
27866/36470ASerial No.  
09/976,9

Applicant

Donald E. Staunton

Filing Date  
10/12/01Group  
1646

## INFORMATION DISCLOSURE STATEMENT

## U.S. PATENT DOCUMENTS

| *Examiner Initials |    | Document Number | Issue Date | Name                   | Class | Subclass | Filing Date if Appropriate |
|--------------------|----|-----------------|------------|------------------------|-------|----------|----------------------------|
|                    | A1 | 5,847,088       | 12/08/98   | Cousens <i>et al.</i>  | 530   | 388.1    |                            |
|                    | A2 | 5,888,809       | 03/30/99   | Allison                | 435   | 325      |                            |
|                    | A3 | 6,251,395       | 06/26/01   | Gallatin <i>et al.</i> | 424   | 144.1    |                            |
|                    |    |                 |            |                        |       |          |                            |
|                    |    |                 |            |                        |       |          |                            |

## FOREIGN PATENT DOCUMENTS

| *Examiner Initials |  | Document Number | Publication Date | Country | Class | Subclass | Translation |    |
|--------------------|--|-----------------|------------------|---------|-------|----------|-------------|----|
|                    |  |                 |                  |         |       |          | Yes         | No |
|                    |  |                 |                  |         |       |          |             |    |
|                    |  |                 |                  |         |       |          |             |    |

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

|  |    |  |
|--|----|--|
|  |    |  |
|  | C1 | Aghazdeh <i>et al.</i> , "Structural Basis for Relief of Autoinhibition of the Dbl Homology Domain of Proto-Oncogene Vav by Tyrosine Phosphorylation," <i>Cell</i> , 102:625-633 (Sept. 1, 2000) |
|  | C2 | Amyes <i>et al.</i> , "Trimethoprim-Sensitivity Testing and Thymineless Mutants," <i>J. Med. Microbiol.</i> , 7(2):143-153 (1974)  |
|  | C3 | Andersen <i>et al.</i> , "Protein export and drug efflux through bacterial channel-tunnels," <i>Curr. Opin. Cell Biol.</i> , 13:412-416 (2001)   |
|  | C4 | Ausubel <i>et al.</i> , "Enzymatic Amplification of DNA by PCR: Standard Procedures and Optimization," <i>Curr. Protocols Mol. Biol.</i> , 3:15.1.1-15.1.14 (2001)                               |
|  | C5 | Baldock <i>et al.</i> , "A Mechanism of Drug Action Revealed by Structural Studies of Enoyl Reductase," <i>Science</i> , 274:2107-2110 (Dec. 20, 1996)   |
|  | C6 | Berge <i>et al.</i> , "Pharmaceutical Salts," <i>J. Pharmaceutical Sciences</i> , 66(1):1-19 (Jan., 1977)  |
|  | C7 | Bollag <i>et al.</i> , "Epothilones, a New Class of Microtubule-stabilizing Agents with a Taxol-like Mechanism of Action" <i>Cancer Research</i> , 55:2325-2333 (June 1, 1995)                   |

|  |                 |
|--|-----------------|
| EXAMINER   | DATE CONSIDERED |
| *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance <u>and</u> not considered. Include copy of this form with next communication to applicant. |                 |



|   |  |  |                                  |                        |
|---|--|--|----------------------------------|------------------------|
| m PTO-1449 (Modified)                   |  | U.S. Department of Commerce<br>Patent and Trademark Office | Atty. Docket No.<br>27866/36470A | Serial No.<br>09/976,9 |
| <b>INFORMATION DISCLOSURE STATEMENT</b> |  |  | Applicant<br>Donald E. Staunton  |                        |
|   |  |  | Filing Date<br>10/12/01          | Group<br>1646          |

RECEIVED  
AUG 27 2002  
TECH. CENTER 1600/2900

|     |  |
|-----|--|
| C8  | Briesewitz <i>et al.</i> , "Expression of Native and Truncated Forms of the Human Integrin $\alpha_1$ Subunit," <i>J. Biol. Chem.</i> , 268(4):2989-2996 (February 5, 1993)  |
| C9  | Chang <i>et al.</i> , "A general method for facilitating heterodimeric pairing between two proteins: Application to expression of $\alpha$ and $\beta$ T-cell receptor extracellular segments," <i>Proc. Nat'l. Acad. Sci. (USA)</i> , 91:11408-11412 (November, 1994) |
| C10 | Copley <i>et al.</i> , "Protein families in multicellular organisms," <i>Curr. Opin. Struct. Biol.</i> , 9:408-415 (1999)  |
| C11 | Couzin, "Integrin Crystal Structure Solved," <i>Science</i> , 293:1743-1746 (September 7, 2001)  |
| C12 | Cranmer <i>et al.</i> , "Glycoprotein (GP) Ib-IX-transfected Cells Roll on a von Willebrand Factor Matrix under Flow," <i>J. Biol. Chem.</i> , 274(10):6097-6106 (March 5, 1999)   |
| C13 | Crompton <i>et al.</i> , "Regulation of Tiam1 Nucleotide Exchange Activity by Pleckstrin Domain Binding Ligands," <i>J. Biol. Chem.</i> , 275(33):25751-25759 (August 18, 2000)  |
| C14 | deFougerolles <i>et al.</i> , "Regulation of inflammation by collagen-binding integrins $\alpha 1\beta 1$ and $\alpha 2\beta 1$ in models of hypersensitivity and arthritis," <i>J. Clin. Invest.</i> , 105(6):721-729 (March, 2000)                                   |
| C15 | De Vos <i>et al.</i> , "Three-Dimensional Structure of an Oncogene Protein: Catalytic Domain of Human c-H-ras p21," <i>Science</i> , 239:888-893 (February 19, 1988)   |
| C16 | Diamond <i>et al.</i> , "The I Domain Is a Major Recognition Site on the Leukocyte Integrin Mac-1(CD11b/CD18) for Four Distinct Adhesion Ligands," <i>J. Cell Biology</i> , 120(4):1031-1043 (February, 1993)  |
| C17 | Dickeson <i>et al.</i> , "Ligand recognition by the I domain-containing integrins," <i>Cell. Mol. Life Sci.</i> , 54:556-566 (1998)  |
| C18 | Didsbury <i>et al.</i> , "rac, a Novel ras-related Family of Proteins That Are Botulinum Toxin Substrates," <i>J. Biol. Chem.</i> , 264(28):16378-16382 (October 5, 1989)  |
| C19 | Edwards <i>et al.</i> , "The protein fold of the von Willebrand factor type A domain is predicted to be similar to the open twisted $\beta$ -sheet flanked by $\alpha$ -helices found in human ras-p21," <i>FEBS Letter</i> , 358:283-286 (1995)                       |
| C20 | Eliopoulos <i>et al.</i> , "Antimicrobial Combinations," in <i>Antibiotics in Laboratory Medicine</i> , 4 <sup>th</sup> Ed., pp. 330-396, (V. Lorian, ed., 1996)   |
| C21 | Emsley <i>et al.</i> , "Crystal Structure of the I Domain from Integrin $\alpha 2\beta 1$ ," <i>J. Biol. Chem.</i> , 272(45):28512-28517 (November 7, 1997)  |
| C22 | Emsley <i>et al.</i> , "Structural Basis of Collagen Recognition by Integrin $\alpha 2\beta 1$ ," <i>Cell</i> , 101:47-56 (March 31, 2000)   |

|  |                 |
|--|-----------------|
| EXAMINER   | DATE CONSIDERED |
| *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance <u>and</u> not considered. Include copy of this form with next communication to applicant. |                 |



Sheet of 5

TECH CENTER 1600/2900

RECEIVED  
AUG 27 2002

|                                  |  |  |  |                                  |                        |  |  |
|----------------------------------|--|--|--|----------------------------------|------------------------|--|--|
| in PTO-1449 (Modified)           |  | U.S. Department of Commerce<br>Patent and Trademark Office |  | Atty. Docket No.<br>27866/36470A | Serial No.<br>09/976,9 |  |  |
| INFORMATION DISCLOSURE STATEMENT |  |  |  | Applicant<br>Donald E. Staunton  |                        |  |  |
|                                  |  |  |  | Filing Date<br>10/12/01          | Group<br>1646          |  |  |

|     |  |
|-----|--|
| C23 | Gibrat <i>et al.</i> , "Surprising similarities in structure comparison," <i>Curr. Opin. Struct. Biol.</i> , 6:377-385 (1996)  |
| C24 | Hahn <i>et al.</i> , "The complete sequences of plasmids pFNeo and pMN-Neo: convenient expression vectors for high-level expression of eukaryotic genes in hematopoietic cell lines," <i>Gene</i> , 127:267-268 (1993)                                     |
| C25 | Hardma <i>et al.</i> , eds., "Pharmacokinetics," Goodman & Gilman's The Pharmacological Basis of Therapeutics, Ninth Edition, New York, New York, McGraw-Hill, Chapter 1, pp. 11-16 (1996)   |
| C26 | Higuchi <i>et al.</i> , eds., "Prodrug as Novel Drug Delivery Systems, ACS Symposium Series, 14, table of contents only (1975)   |
| C27 | Higuchi, "Prodrug and Drug Delivery - An Overview," Bioreversible Carriers in Drug Design Theory and Application, Roche ed., Pergamon Press, Chapter 1, pp. 1-12, (1987)   |
| C28 | Hitchings and Baccanari, "Design and Synthesis of Folate Antagonists as Antimicrobial Agents", in <i>Folate Antagonists as Therapeutic Agents</i> , Chapter 4, Vol. 1:151-172 (1984)   |
| C29 | Hua Jing <i>et al.</i> , "New structural motifs on the chymotrypsin fold and their potential roles in complement factor B," <i>EMBO J.</i> , 19(2):164-173 (2000)  |
| C30 | Huth <i>et al.</i> , "NMR and mutagenesis evidence for an I domain allosteric site that regulates lymphocyte function-associated antigen 1 ligand binding," <i>Proc. Nat'l. Acad. Sci. (USA)</i> , 97(10):5231-5236 (May 9, 2000)                          |
| C31 | Kirshenbaum <i>et al.</i> , "Predicting allosteric switches in myosins," <i>Protein Science</i> , 8:1806-1815 (1999)   |
| C32 | Lee <i>et al.</i> , "Crystal Structure of the A Domain from the $\alpha$ Subunit of Integrin CR3 (CD11b/CD18)," <i>Cell</i> , 80:631-638 (February 24, 1995)   |
| C33 | Lochter <i>et al.</i> , " $\alpha 1$ and $\alpha 2$ Integrins Mediate Invasive Activity of Mouse Mammary Carcinoma Cells through Regulation of Stromelysin-1 Expression," <i>Mol. Biol. Cell</i> , 10:271-282 (February, 1999)                             |
| C34 | Madej <i>et al.</i> , "Threading a Database of Protein Cores," <i>Proteins: Structure, Functions and Genetics</i> , 23:356-369 (1995)  |
| C35 | Mandell <i>et al.</i> , "Sulfonamides, Trimethoprim-Sulfamethoxazole, Quinolones, and Agents for Urinary Tract Infections," in <i>The Pharmacological Basis of Therapeutics</i> Chapter 44, Antimicrobial Agents, 1057-1072(Goodman and Gilman eds., 1996) |
| C36 | Nelson <i>et al.</i> , "Matrix Metalloproteinases: Biologic Activity and Clinical Implications," <i>J. Clin. Oncol.</i> , 18(5):1135-1149 (March, 2000)  |

|  |                 |
|--|-----------------|
| EXAMINER   | DATE CONSIDERED |
| *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance <u>and</u> not considered. Include copy of this form with next communication to applicant. |                 |



For PTO-1449 (Modified)

U.S. Department of Commerce  
Patent and Trademark OfficeAtty. Docket No.  
27866/36470ASerial No.  
09/97635

Applicant

Donald E. Staunton

Filing Date  
10/12/01Group  
1646

## INFORMATION DISCLOSURE STATEMENT

TECH. CENTER 1600/2900

AUG 27 2002

RECEIVED

|     |  |
|-----|--|
| C37 | Nobes, "Rho GTPases and Cell Migration-Fibroblast Wound Healing," <i>Meth. Enzymol.</i> , 325:441-449 (2000)   |
| C38 | Nogales <i>et al.</i> , "Tubulin and FtsZ form a distinct family of GTPases," <i>Nature Structural Biology</i> , 5(6):451-458 (June, 1998)   |
| C39 | Oxvig <i>et al.</i> , "Conformational changes in tertiary structure near the ligand binding site of an integrin I domain," <i>Proc. Nat'l. Acad. Sci. (USA)</i> , 96:2215-2220 (March, 1999)   |
| C40 | Pozzi <i>et al.</i> , "Elevated matrix metalloprotease and angiostatin levels in integrin $\alpha 1$ knockout mice cause reduced tumor vascularization," <i>Proc. Nat'l. Acad. Sci. (USA)</i> , 97(5):2202-2207 (February 29, 2000)  |
| C41 | Ponting <i>et al.</i> , "SMART: identification and annotation of domains from signalling and extracellular protein sequences," <i>Nucl. Acids Res.</i> , 27(1):226-229 (1999)  |
| C42 | Poste <i>et al.</i> , "Lipid Vesicles as Carriers for Introducing Biologically Active Materials into Cells," <i>Methods in Cell Biology</i> , Vol. XIV, Academic Press, New York, New York, Prescott, ed., Chapter 4, pp. 33-71 (1976)   |
| C43 | Qu <i>et al.</i> , "The role of the divalent cation in the structure of the I domain from the CD11a/CD18 integrin," <i>Structure</i> , 4:931-942 (August 15, 1996)   |
| C44 | Rich <i>et al.</i> , "Trench-shaped Binding Sites promote Multiple Classes of Interactions between Collagen and the Adherence Receptors, $\alpha_1\beta_1$ Integrin and <i>Staphylococcus aureus</i> Can MSCRAMM," <i>J. Biol. Chem.</i> , 274(35):24906-24913 (August 27, 1999) |
| C45 | Richey <i>et al.</i> , "The Biosynthesis of Folic Acid," <i>J. Biol. Chem.</i> , 244(6):1582-1592 (March 25, 1969)   |
| C46 | Rossmann <i>et al.</i> , "Bacterial Expressed DH and DH/PH Domains," <i>Meth. Enzymol.</i> , 325:25-38 (2000)  |
| C47 | Rost, "PHD: Predicting One-Dimensional Protein Structure by Profile-Based Neural Networks," <i>Meth. Enzymol.</i> , 266:525-539 (1996)   |
| C48 | Sadhu <i>et al.</i> , "LFA-1 Binding Site in ICAM-3 Contains a Conserved Motif and Non-Cotniguous Amino Acids," <i>Cell Adhes. Commun.</i> , 2:429-440 (1994)  |
| C49 | Scita <i>et al.</i> , "Signaling from Ras to Rac and beyond: not just a matter of GEFs," <i>EMBO J.</i> , 19(11):2393-2398 (2000)  |
| C50 | Schultz <i>et al.</i> , "SMART, a simple modular architecture research tool: Identification of signaling domains," <i>Proc. Nat'l. Acad. Sci. (USA)</i> , 95:5857-5864 (May, 1998)   |
| C51 | Schultz <i>et al.</i> , "SMART: a web-based tool for the study of genetically mobile domains," <i>Nucl. Acids Res.</i> , 28(1):231-234 (2000)  |
| C52 | Self <i>et al.</i> , "Purification of Recombinant Rho/Rac/G25K from <i>Escherichia coli</i> ," <i>Meth. Enzymol.</i> , 256:3-10 (1995)   |

|  |                 |
|--|-----------------|
| EXAMINER   | DATE CONSIDERED |
| *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance <u>and</u> not considered. Include copy of this form with next communication to applicant. |                 |



RECEIVED

AUG 27 2002

TECH CENTER 1600/2900

For mpep O-1449 (Modified)

U.S. Department of Commerce  
Patent and Trademark OfficeAtty. Docket No.  
27866/36470ASerial No.  
09/976,

Applicant

Donald E. Staunton

Filing Date  
10/12/01Group  
1646

## INFORMATION DISCLOSURE STATEMENT

|     |   |
|-----|---|
| C53 | Shi <i>et al.</i> , "Bisubstrate Analogue Inhibitors of 6-Hydroxymethyl-7,8-dihydropterin Pyrophosphokinase: Synthesis and Biochemical and Crystallographic Studies," <i>J. Med. Chem.</i> , 44:1364-1371 (2001)  |
| C54 | Symons, "The Rac and Rho pathways as a source of drug targets for Ras-mediated malignancies," <i>Curr. Opin. in Biotech</i> , 6:668-674 (1995)  |
| C55 | John Wiley & Sons, Inc., "Classical Pathway Evaluation," Current Protocols in Immunology, Coligan <i>et al.</i> , eds. Vol. 3, Chapter 13, Unit 13.1 (2000)   |
| C56 | Velling <i>et al.</i> , "cDNA Cloning and Chromosomal Localization of Human $\alpha_{11}$ Integrin," <i>J. Biol. Chem.</i> , 274(36):25735-25742 (September 3, 1999)  |
| C57 | Worthylake <i>et al.</i> , "Crystal structure of Rac1 in complex with the guanine nucleotide exchange region of Tiam1," <i>Nature</i> , 408:682-688 (December 7, 2000)  |
| C58 | Young <i>et al.</i> , "Predicting conformational switches in proteins," <i>Protein Science</i> , 8:1752-1764 (1999)   |
| C59 | Yu <i>et al.</i> , "Ca <sup>2+</sup> -mediated GTP-dependent dynamic assembly of bacterial cell division protein FtsZ into asters and polymer networks <i>in vitro</i> ," <i>EMBO J.</i> , 16(17):5455-5463 (1997)  |
| C60 | "Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard, <i>National Committee Clinical Laboratory Standards Guidelines</i> , - 5 <sup>th</sup> Ed., Vol. 20, No. 2, pp. 1-27, Wayne, PA (January, 2000) |

|  |                 |
|--|-----------------|
| EXAMINER   | DATE CONSIDERED |
| *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance <u>and</u> not considered. Include copy of this form with next communication to applicant. |                 |